Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, Inc. (“Pearsanta”), has entered into a Market Development Collaboration Agreement (the “Agreement”) with women’s health pioneer Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM) focused on Pearsanta’s blood-based diagnostic test for endometriosis.

SINGAPORE, Sept. 20, 2024 /PRNewswire/ -- Maxeon Solar Technologies, Ltd. (NASDAQ: MAXN) (the "Company"), a global leader in solar innovation and channels, announced that on September 17, 2024, it received a Staff Determination letter (the "Determination Letter") from the staff of the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the Staff's determination to delist the Company's securities from The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) because, as of September 16, 2024, the Company's securities had a closing bid price of $0.10 or less for ten consecutive trading ...

Expected to operate as a community solar site, selling credits to subscribers.Over 640 homes expected to be provided green energy once operational.Eligible to participate in the NYSUN program to receive NYSERDA incentives.TORONTO, Sept. 23, 2024 /PRNewswire/ - SolarBank Corporation (NASDAQ: SUUN; Cboe CA: SUNN, FSE: GY2) ("SolarBank" or the "Company") announces that it intends to develop a 5.4 MW DC ground-mount solar power project known as the Boyle project (the "Project") on a site located in Broome County, New York. The Project is expected to be eligible for incentives under the New York State Energy Research and Development Authority ("NYSERDA") ...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Company’s development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024. The event begins at 9 a.m. ET and will be available via webcast here.